Editing the plasmodium vivax genome, using zinc-finger nucleases

Journal of Infectious Diseases

Volumn 211, Issue 1, 2015, Pages 125-129

  Barros, Roberto R Moraes ^a   Straimer, Judith ^b   Sa, Juliana M ^a   Salzman, Rebecca E ^a   Melendez Muniz, Viviana A ^a   Mu, Jianbing ^a   Fidock, David A ^b,c   Wellems, Thomas E ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b Department of Microbiology and Immunology ^*  (United States)

^c New York Presbyterian Columbia University Medical Center   (United States)

Author keywords

allelic modification; dihydrofolate reductase thymidylate synthase; malaria; pyrimethamine; Saimiri boliviensis.; transfection

Indexed keywords

ATOVAQUONE PLUS PROGUANIL; DIHYDROFOLATE REDUCTASE; DNA; PYRIMETHAMINE; ZINC FINGER NUCLEASE; ANTIMALARIAL AGENT; DEOXYRIBONUCLEASE; PROTOZOAL PROTEIN; ZINC FINGER PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DNA MODIFICATION; DNA REPAIR; DNA SEQUENCE; ELECTROPORATION; ERYTHROCYTE; GENE; GENE MUTATION; GENE SEQUENCE; GENOME; MICROSATELLITE MARKER; MUTANT; NONHUMAN; PARASITEMIA; PLASMID; PLASMODIUM VIVAX; PVDHFR GENE; SAIMIRI BOLIVIENSIS; ANIMAL; DRUG RESISTANCE; GENETICS; MALARIA, VIVAX; PARASITOLOGY; SQUIRREL MONKEY;

ANIMALS; ANTIMALARIALS; DEOXYRIBONUCLEASES; DRUG RESISTANCE; GENES, PROTOZOAN; GENOME, PROTOZOAN; MALARIA, VIVAX; PLASMODIUM VIVAX; PROTOZOAN PROTEINS; PYRIMETHAMINE; SAIMIRI; TETRAHYDROFOLATE DEHYDROGENASE; ZINC FINGERS;

EID: 84922443831     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiu423     Document Type: Article

References (15)

1. Miller LH, Ackerman HC, Su XZ, Wellems TE. Malaria biology and disease pathogenesis: insights for new treatments. Nat Med 2013; 19:156-67.
2. Gruring C, Moon RW, Lim C, Holder AA, Blackman MJ, Duraisingh MT. Human red blood cell-adapted Plasmodium knowlesi parasites: a new model system for malaria research. Cell Microbiol 2014; 16:612-20.
3. Flannery EL, Fidock DA, Winzeler EA. Using genetic methods to define the targets of compounds with antimalarial activity. Eur J Med Chem 2013; 56:7761-71.
4. Janse CJ, Kroeze H, van Wigcheren A, et al. A genotype and phenotype database of genetically modified malaria-parasites. Trends Parasitol 2011; 27:31-9.
5. Menard R, Tavares J, Cockburn I, Markus M, Zavala F, Amino R. Looking under the skin: the first steps in malarial infection and immunity. Nat Rev Microbiol 2013; 11:701-12.
6. Pfahler JM, Galinski MR, Barnwell JW, Lanzer M. Transient transfection of Plasmodium vivax blood stage parasites. Mol Biochem Parasitol 2006; 149:99-101.
7. Gaj T, Gersbach CA, Barbas CF III. ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. Trends Biotechnol 2013; 31:397-405.
8. McNamara CW, Lee MC, Lim CS, et al. Targeting Plasmodium PI(4)K to eliminate malaria. Nature 2013; 504:248-53.
9. Straimer J, Lee MC, Lee AH, et al. Site-specific genome editing in Plasmodium falciparum using engineered zinc-finger nucleases. Nat Methods 2012; 9:993-8.
10. Guan J, Zhang Q, ONeil M, et al. Antimalarial activities of new pyrrolo [3, 2-f ]quinazoline-1, 3-diamine derivatives. Antimicrob Agents Chemother 2005; 49:4928-33.
11. Schmidt LH. Plasmodium falciparum and Plasmodium vivax infections in the owl monkey (Aotus trivirgatus). II. Responses to chloroquine, quinine, and pyrimethamine. Am J Trop Med Hyg 1978; 27:703-17.
12. Doyon Y, Vo TD, Mendel MC, et al. Enhancing zinc-finger-nuclease activity with improved obligate heterodimeric architectures. Nat Methods 2011; 8:74-9.
13. Lee MC, Moura PA, Miller EA, Fidock DA. Plasmodium falciparum Sec24 marks transitional ER that exports a model cargo via a diacidic motif. Mol Microbiol 2008; 68:1535-46.
14. Auliff AM, Balu B, Chen N, ONeil MT, Cheng Q, Adams JH. Functional analysis of Plasmodium vivax dihydrofolate reductase-thymidylate synthase genes through stable transformation of Plasmodium falciparum. PLoS One 2012; 7:e40416.
15. Tjitra E, Baker J, Suprianto S, Cheng Q, Anstey NM. Therapeutic efficacies of artesunate-sulfadoxine-pyrimethamine and chloroquinesulfadoxine- pyrimethamine in vivax malaria pilot studies: relationship to Plasmodium vivax dhfr mutations. Antimicrob Agents Chemother 2002; 46:3947-53.